Internal medicine

Pathology

Clinical endpoint

Placebo

Quality of life (healthcare)

Prostate cancer

Docetaxel

Cancer

Nursing

Oncology

Physical therapy

Randomized controlled trial

Alternative medicine

Brief Pain Inventory

Androgen deprivation therapy

Chronic pain

Medicine

The Lancet Oncology

Apalutamide with ADT is a well-tolerated and effective option for men with metastatic castration-sensitive prostate cancer. The combination significantly improves survival outcomes compared with ADT alone while maintaining HRQOL despite additive androgen blockade.

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study